Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Won Jin Ho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2644-5086; OpenAlex author ID A5048843293; NIH RePORTER profile ID 12442814. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 5)
Trials
0
Grants
1
Labs led
1
Collaborators
68
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers, 1 grant · 2022: none · 2023: none · 2024: 4 papers · 2025: 2 papers · 2026: 10 papers

Papers 20

  1. Quantitative 3D histology reveals localized immune remodeling during early pancreatic cancer progression. Co-author DOI 10.1016/j.cpblue.2026.100008↗
  2. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  3. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  4. Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-0331↗
  5. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  6. A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC. Last author DOI 10.1158/2326-6066.cir-25-0545↗
  7. Computational Modeling of Cellular Influence Delineates Functionally Relevant and Distinct Cellular Neighborhoods in Primary and Metastatic Pancreatic Ductal A… Last author DOI 10.1158/2326-6066.cir-25-0844↗
  8. Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses. Last author DOI 10.1158/2326-6066.cir-25-1126↗
  9. Periductal Fibroblast Density Defines Lymphocyte Exclusion via a CD44-Dependent Stromal Checkpoint in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-25-1481↗
  10. Deep Learning Enabled 3D Multi-Omic Analysis Reveals Molecular Signatures of Heterogeneous Response to Chemotherapy in Pancreatic Cancer Co-author DOI 10.64898/2026.03.03.709150↗
  11. CD137 agonism enhances anti-PD1 induced activation of expanded CD8+ T cell clones in a neoadjuvant pancreatic cancer clinical trial. Co-author DOI 10.1016/j.isci.2024.111569↗
  12. A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrop… Last author DOI 10.1080/2162402x.2025.2543614↗
  13. Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101397↗
  14. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Co-author DOI 10.1038/s41467-024-52528-7↗
  15. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
  16. Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci.insight.179292↗
  17. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
  18. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Co-author DOI 10.1186/s13059-021-02363-6↗
  19. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Co-author DOI 10.1038/s41571-020-0363-5↗
  20. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗

Grants 1

  1. Immunophenotype Integration for Monitoring T Cell Dynamics in Pancreatic Cancers R21CA264004↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 16 shared papers, 2020–2026 · strength 2.78
  2. Elana Judith Fertig · 13 shared papers, 2020–2026 · strength 2.29
  3. Luciane Tsukamoto Kagohara · 9 shared papers, 2021–2026 · strength 1.56
  4. Katherine M. Bever · 8 shared papers, 2020–2026 · strength 1.46
  5. Jae Woo Lee · 7 shared papers, 2024–2026 · strength 1.46
  6. Dimitrios N. Sidiropoulos · 7 shared papers, 2024–2026 · strength 1.28
  7. Robert A. Anders · 7 shared papers, 2020–2026 · strength 1.19
  8. Nicole Groß · 7 shared papers, 2021–2026 · strength 1.17
  9. Mark M. Yarchoan · 7 shared papers, 2021–2026 · strength 1.08
  10. Hao Wang · 5 shared papers, 2026 · strength 1.03
  11. Janelle Marie Montagne · 5 shared papers, 2024–2026 · strength 0.92
  12. Amanda L. Huff · 5 shared papers, 2021–2026 · strength 0.91
  13. Dung Thi Le · 5 shared papers, 2020–2026 · strength 0.88
  14. Lei Zheng · 6 shared papers, 2020–2026 · strength 0.87
  15. Marina Baretti · 5 shared papers, 2021–2026 · strength 0.83
  16. Nilofer Saba Azad · 5 shared papers, 2021–2026 · strength 0.83
  17. Neeha Zaidi · 5 shared papers, 2021–2026 · strength 0.78
  18. Jacob T. Mitchell · 4 shared papers, 2024–2026 · strength 0.74
  19. Laura DeLong Wood · 3 shared papers, 2026 · strength 0.73
  20. Daniel A. Laheru · 4 shared papers, 2020–2026 · strength 0.67
  21. Yeonju Cho · 3 shared papers, 2024–2026 · strength 0.63
  22. Ashley L. Kiemen · 3 shared papers, 2024–2026 · strength 0.60
  23. Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
  24. André Forjaz · 2 shared papers, 2026 · strength 0.46
  25. Denis Wirtz · 2 shared papers, 2026 · strength 0.46

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.